| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3582 |
| Trial ID | NCT06027957 |
| Disease | B-Cell Non-Hodgkin's Lymphoma | B-Cell Acute Lymphoblastic Leukemia |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Phase I Clinical Trial Evaluating the Safety and Efficacy of Point-of-care CAR-T-cell Therapy in the Treatment of Relapsed/Refractory CD19+ Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia |
| Year | 2023 |
| Country | Vietnam |
| Company sponsor | Vinmec Research Institute of Stem Cell and Gene Technology |
| Other ID(s) | ISC19.26 |
| Cohort 1 | |||||||||
|
|||||||||